Clinical significance of serum and urinary HER2/neu protein levels in primary non-muscle invasive bladder cancer

Basit Öğe Kaydı
dc.contributor.authorArikan O.
dc.contributor.authorYyldyrym A.
dc.contributor.authorYsbilen B.
dc.contributor.authorCanakci C.
dc.contributor.authorAtys G.
dc.contributor.authorGurbuz C.
dc.contributor.authorCaskurlu T.
dc.date.accessioned2019-08-01T13:38:39Z
dc.date.available2019-08-01T13:38:39Z
dc.date.issued2015
dc.departmentNiğde ÖHÜ
dc.description.abstractObjective: We aimed to compare serum and urinary HER2/neu levels between healthy control group and patients with non-muscle invasive bladder cancer. Additionally, we evaluated relationship of HER2/neu levels with tumor stage, grade, recurrence and progression. Materials and Methods: Fourty-four patients with primary non-muscle invasive bladder tumors (Group 2) and 40 healthy control group (Group 1) were included the study. Blood and urinary samples were collected from all patients and HER2/neu levels were measured by ELISA method. Blood and urinary HER2/neu levels and additionally, ratio of urinary HER2/neu levels to urinary creatinine levels were recorded. Demographic data and tumor characteristics were recorded. Results: Mean serum HER2/neu levels were similar between two groups and statistically significant difference wasn't observed. Urinary HER2/neu levels were significantly higher in group 2 than group 1. Ratio of urinary HER2/neu to urinary creatinine was significantly higher in group 2 than group 1, (p=0,021). Serum and urinary HER2/ neu levels were not associated with tumor stage, grade, recurrence and progression while ratio of urinary HER2/neu to urinary creatinin levels were significantly higher in high-grade tumors. HER2/neu, the sensitivity of the test was found to be 20.5%, and the specificity was 97.5%, also for the urinary HER2/neu/urinary creatinine ratio, the sensitivity and specificity of the test were found to be 31.8% and 87.5%, respectively. Conclusions: Urinary HER2/neu and ratio of urinary creatinine urine were significantly higher in patients with bladder cancer compared to healthy subjects. Large series and controlled studies are needed for use as a tumor marker.
dc.identifier.doi10.1590/S1677-5538.IBJU.2014.0628
dc.identifier.endpage1087
dc.identifier.issn1677-5538
dc.identifier.issue6
dc.identifier.pmid26742964
dc.identifier.startpage1080
dc.identifier.urihttps://dx.doi.org/10.1590/S1677-5538.IBJU.2014.0628
dc.identifier.urihttps://hdl.handle.net/11480/1966
dc.identifier.volume41
dc.indekslendigikaynakPubMed
dc.institutionauthor[0-Belirlenecek]
dc.language.isoen
dc.publisherBrazilian Society of Urology
dc.relation.ispartofInternational Braz J Urol
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectHER2-neu-derived peptide (654-662) [supplementary concept]
dc.subjectSerum
dc.subjectUrinary bladder eoplasms
dc.titleClinical significance of serum and urinary HER2/neu protein levels in primary non-muscle invasive bladder cancer
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu